Onset of symptom relief with rabeprazole: a community‐based, open‐label assessment of patients with erosive oesophagitis

Open Access
Publisher Website
Google Scholar
Abstract
Background: In numerous clinical trials, proton pump inhibitors have demonstrated potent acid suppression and healing of erosive oesophagitis, as well as successful symptom relief for the entire spectrum of gastro‐oesophageal reflux disease. Aim: The `Future of Acid Suppression Therapy' (FAST) trial evaluated, in actual clinical practice, the timing of symptom relief, changes in symptom severity, health‐related quality of life and safety in endoscopically confirmed erosive gastro‐oesophageal reflux disease treated with rabeprazole. Methods: This open‐label, multicentre study enrolled 2579 patients to receive rabeprazole treatment using 20 mg once daily for 8 weeks. Between two clinical visits (at enrolment and week 8), patients used an interactive voice response system to rate gastro‐oesophageal reflux disease symptoms. Subgroup analyses of efficacy were conducted for gender, age, Hetzel–Dent grade, presence of Barrett's oesophagus and for patients reporting previously ineffective symptom relief with omeprazole or lansoprazole. Results: On day 1, rabeprazole significantly decreased daytime and night‐time heartburn severity, regurgitation and belching. Complete relief of daytime and night‐time heartburn was achieved in 64.0% and 69.2% of symptomatic patients, respectively, on day 1, and in 81.1% and 85.7% of patients, respectively, on day 7. Patients with moderate or severe heartburn symptoms at baseline achieved an even greater degree of satisfactory symptom relief (none or mild) from day 1 onwards. The median time to satisfactory heartburn relief was 2 days. Subgroup analyses showed no consistent differences in efficacy compared to the overall population treated. Health‐related quality of life in patients was significantly lower than that of the US general population and improved significantly after 8 weeks of rabeprazole therapy. Rabeprazole was well tolerated, with headache as the most common adverse event, reported by less than 2% of the study population. Conclusions: In this large, open‐label trial, rabeprazole rapidly and effectively relieved gastro‐oesophageal reflux disease symptoms in most patients with erosive oesophagitis. Substantial symptom relief was noted on day 1; improvement continued over the first week and at week 4. By week 8, the health‐related quality of life had also improved vs. baseline.

This publication has 20 references indexed in Scilit: